<DOC>
	<DOCNO>NCT00000659</DOCNO>
	<brief_summary>Part 1A : To find dose zidovudine ( AZT ) cause less 50 percent drop HIV-1 p24 antigen level patient AIDS advance AIDS relate complex ( ARC ) ; determine pharmacokinetics ( blood level ) rsCD4 administer combination AZT . Parts 1B 2 : To test additive synergistic activity rsCD4 AZT judge fall HIV-1 p24 antigen level ; evaluate safety rsCD4 AZT patient AIDS advance ARC . AZT show effective treatment AIDS advance ARC without toxicity . The clinically significant toxicity dose related inhibition bone marrow function . Furthermore , HIV-1 isolate patient treat 6 month AZT find appear reduce sensitivity AZT . The incidence toxicity occurrence virus reduce sensitivity AZT may result inability administer AZT long-term patient AIDS advance ARC . Recombinant soluble CD4 ( rCD4 ) show antiretroviral effect show safe give AIDS ARC patient either single agent combination AZT .</brief_summary>
	<brief_title>A Phase II Trial rsCD4 AZT Patients With AIDS Advanced AIDS Related Complex ( ARC )</brief_title>
	<detailed_description>AZT show effective treatment AIDS advance ARC without toxicity . The clinically significant toxicity dose related inhibition bone marrow function . Furthermore , HIV-1 isolate patient treat 6 month AZT find appear reduce sensitivity AZT . The incidence toxicity occurrence virus reduce sensitivity AZT may result inability administer AZT long-term patient AIDS advance ARC . Recombinant soluble CD4 ( rCD4 ) show antiretroviral effect show safe give AIDS ARC patient either single agent combination AZT . Part 1A : Twenty p24+ patient AIDS advance ARC randomize 4 dose group 5 patient . Patients treat AZT 6 week range dos determine minimally effective dose ( MED ) . At end week 6 , patient sequentially assign 1 5 group rCD4 / AZT combination treatment . The first 3 patient complete treatment week 6 treat group A , next 3 patient group B , . The treatment period 4 week . Each patient continue AZT dose initially administer . The high dose AZT produce less 50 percent drop HIV-1 p24 antigen level least 3 5 patient 6 week MED AZT know AZT MED . After MED determine , Part 1B begin . Part 1B : 20 patient randomized 2 different dose group : Group 5 : AZT MED ( week 1 8 ) , AZT MED plus rCD4 ( week 9 16 ) ; Group 6 : AZT MED plus rCD4 ( week 1 8 ) , AZT MED ( week 9 16 ) . Part 2 : Part 2 begin accrual Part 1B complete . If few 10 20 patient exhibit drop least 50 percent p24 antigen level receive AZT rsCD4 combination treatment , entry Part 2 interrupt study design reevaluate . In Part 2 , 10 patient randomly assign one four group . Patients within group receive two 8 week treatment course . These two treatment course 8 week AZT MED alone , 8 week treatment combination AZT MED plus rCD4 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Nystatin clotrimazole suppression oral thrush . Aerosolized pentamidine chemoprophylaxis Pneumocystis carinii pneumonia ( PCP ) . Trimethoprim / sulfamethoxazole ( TMP / SMX ) patient clinically hematologically stable TMP / SMX PCP prophylaxis . Patients must follow : Diagnosis AIDS advance AIDS relate complex ( ARC ) . CD4 cell count &lt; 300 cells/mm3 . Ability understand sign consent form . Risk Behavior : Allowed : History drug abuse current abstinence enrollment methadone treatment program . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Malignancies Kaposi 's sarcoma . AIDS dementia , opinion investigator , preclude patient give fully inform consent comply fully requirement protocol . Active infection opportunistic pathogen require ongoing therapy . Preexisting antibody rCD4 . Concurrent Medication : Excluded : Investigational drug . Antiretroviral agent dextran sulfate AL721 . Cytotoxic chemotherapy . Concurrent Treatment : Excluded : Radiation therapy . Patients follow exclude : Malignancies Kaposi 's sarcoma . AIDS dementia , opinion investigator , preclude patient give fully inform consent comply fully requirement protocol . Active infection opportunistic pathogen require ongoing therapy . Preexisting antibody rCD4 . Prior Medication : Excluded : Zidovudine ( AZT ) longer 30 day prior treatment AZT &lt; 30 day discontinue toxicity due AZT . Excluded within 30 day study entry : Immunomodulators . Previous participation group another part study . For example , patient treat Part 1A study may reenter study treat Part 2 . Chemotherapy . Prior Treatment : Excluded within 30 day study entry : Radiation therapy . Active use illicit drug abuse alcohol time protocol entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1990</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antigens , CD4</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>